Champions Oncology Inc (OQ:CSBR)
Business Focus: Biotechnology & Medical Research
Mar 12, 2024 04:30 pm ET
Champions Oncology Reports Quarterly Revenue of $12.0 Million
HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2024, ended January 31, 2024.
Mar 07, 2024 09:00 am ET
Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced that the College of American Pathologists (CAP) has awarded accreditation to its US-based laboratory.
Mar 06, 2024 04:35 pm ET
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024
HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 860900. A replay of the call will be available
Dec 12, 2023 04:00 pm ET
Champions Oncology Reports Quarterly Revenue of $11.6 Million
HACKENSACK, NJ / ACCESSWIRE / December 12, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2024, ended October 31, 2023.
Dec 04, 2023 04:30 pm ET
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023
HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 589886. A replay of the call will be av
Nov 02, 2023 08:30 am ET
Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification
HACKENSACK, NJ / ACCESSWIRE / November 2, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced its European research operations site in Bresso, Italy, received ISO-9001:2015 laboratory accreditation from the Bureau Veritas S.p.A. and ATS certification from the Lombardy Region.
Oct 17, 2023 08:30 am ET
Champions Oncology Announces the Addition of Brady Davis as President
HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth.
Sep 13, 2023 04:00 pm ET
Champions Oncology Reports Quarterly Revenue of $12.6 Million
HACKENSACK, NJ / ACCESSWIRE / September 13, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2024, ended July 31, 2023.
Sep 11, 2023 04:00 pm ET
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 13, 2023
HACKENSACK, NJ / ACCESSWIRE / September 11, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2023, on Wednesday, September 13, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access
Aug 22, 2023 08:30 am ET
Champions Oncology Aannounces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023
HACKENSACK, NJ / ACCESSWIRE / August 22, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, kicks-off its annual series of events by hosting a scientific symposium at the Museum of Science, in Boston, Massachusetts on September 26th.
Aug 01, 2023 08:45 am ET
Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies
HACKENSACK, NJ / ACCESSWIRE / August 1, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, today announced an agreement to adopt BioVolume's leading 3D imaging and thermal technology as their primary means of capturing efficacy results. Through this multi-year agreement Champions Oncology will incorporate BioVolume's cutting-edge thermal and 3D imaging platform into its broad portfolio of in vivo preclinical offerings. In alignment with Champions consistent focus
Jul 24, 2023 04:00 pm ET
Champions Oncology Reports Quarterly Revenue of $13.1 Million
Record Annual Revenue of $53.9 Million
Jul 20, 2023 04:00 pm ET
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023
HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter and year ended April 30, 2023, on Monday, July 24, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access co
Apr 17, 2023 08:30 am ET
Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development
HACKENSACK, NJ / ACCESSWIRE / April 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic (PPMO) integration, announced the launch of its therapeutic discovery and development platform into a wholly owned subsidiary named Corellia AI (Corellia). Corellia launches out of Champions Oncology with a team of world class scientists advancing a robust pipeline of therapeutic programs and a unique discovery and development platform. The compa
Apr 05, 2023 09:50 am ET
Champions Oncology Announces $5M Stock Repurchase Program
HACKENSACK, NJ / ACCESSWIRE / April 5, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $5 million of its common stock through April 30, 2024 pursuant to Rule 10b-18 of the Securities Exchange Act of 1934.
Mar 15, 2023 03:50 pm ET
Champions Oncology Reports Quarterly Revenue of $12.8 Million
HACKENSACK, NJ / ACCESSWIRE / March 15, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2023, ended January 31, 2023.
Mar 13, 2023 08:30 am ET
Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023
HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the acces
Dec 13, 2022 04:00 pm ET
Champions Oncology Reports Record Quarterly Revenue of $14.3 Million
HACKENSACK, NJ / ACCESSWIRE / December 13, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its second quarter of fiscal 2023, ended October 31, 2022.
Dec 09, 2022 04:30 pm ET
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022
HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access c
Sep 08, 2022 04:00 pm ET
Champions Oncology Reports Record Quarterly Revenue of $13.7 Million
HACKENSACK, NJ / ACCESSWIRE / September 8, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2023, ended July 31, 2022.
Sep 06, 2022 04:00 pm ET
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022
HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the acc
Jul 21, 2022 04:00 pm ET
Champions Oncology Reports Quarterly Revenue of $12.9 Million
Record Annual Revenue of $49.1 Million
Jul 14, 2022 04:00 pm ET
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022
HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter ended April 30, 2022, on Thursday, July 21, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 9086
May 31, 2022 08:30 am ET
Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics
HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc. ("Cyclica"), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, announced today a therapeutic development partnership.
May 03, 2022 08:30 am ET
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo
HACKENSACK, NJ / ACCESSWIRE / May 3, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today that its Lumin Bioinformatics Platform has been selected as a finalist for the ‘Best in Show' Competition at the upcoming Bio-IT World Conference & Expo. The company will present an overview and live demonstration of the platform to judges on May 4th.
Mar 15, 2022 04:45 pm ET
Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million
HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2022, ended January 31, 2022.
Mar 11, 2022 08:30 am ET
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022
HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 69
Feb 15, 2022 08:30 am ET
Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors
HACKENSACK, NJ / ACCESSWIRE / February 15, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a co-development partnership with GigaMune. The partnership will combine Champions' novel Autologous Tumor Infiltrating Lymphocyte (TIL) platform with GigaMune's T Cell Receptor (TCR) Discovery platform to accelerate the development of next generation T cell therapies and cancer di
Jan 20, 2022 08:30 am ET
Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates
HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a therapeutic co-development partnership with Fannin Innovation Studio. The partnership will combine novel therapeutic targets identified within Champions' Lumin platform with Fannin's Therapeutic Raptamer platform to develop next generation Raptamer Drug Conjugates (RDC's). RDCs engage tu
Jan 04, 2022 08:30 am ET
Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs
HACKENSACK, NJ / ACCESSWIRE / January 4, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today a therapeutic development partnership with Alloy Therapeutics. The partnership will combine novel therapeutic targets identified within Champions' Lumin platform with Alloy's fully-integrated in vivo and in vitro antibody discovery, optimization, and lead development services pla
Dec 13, 2021 04:20 pm ET
Champions Oncology Reports Record Quarterly Revenue of $11.8 Million
Reported income from operations of $263,000
Dec 06, 2021 09:20 am ET
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 13, 2021
HACKENSACK, NJ / ACCESSWIRE / December 6, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), leaders in transformative technology solutions utilized in oncology drug discovery and development will report its financial and operational results for the second quarter ended October 31, 2021, on Monday, December 13, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 877-545-0320 (Domestic) or 973-528-0002 (International) and enter the access code 694190.A replay of the call will be av
Oct 20, 2021 10:25 am ET
Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus
HACKENSACK, NJ / ACCESSWIRE / October 20, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZone Life Sciences Campus in Bresso, Italy, on the doorstep of Milan.
Sep 13, 2021 04:00 pm ET
Champions Oncology Reports Record Quarterly Revenue of $11.3 Million
HACKENSACK, NJ / ACCESSWIRE / September 13, 2021 / Champions Oncology, Inc. (Nasdaq:CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 2022, ended July 31, 2021.
Sep 02, 2021 04:30 pm ET
Jul 26, 2021 08:30 am ET
Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development
HACKENSACK, NJ / ACCESSWIRE / July 26, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space. Champions is organized as a dynamic ecosystem of business units centered around a world leading oncology research center that is based off a unique & proprietary set of data and experimental platforms. The co
Jul 22, 2021 08:00 am ET
Champions Oncology Reports Quarterly Revenue of $10.6 Million
Record Annual Revenue of $41 Million
Jul 14, 2021 08:30 am ET
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 22, 2021
HACKENSACK, NJ / ACCESSWIRE / July 14, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2021, on Thursday, July 22, 2021, before market open. The company will host a conference call to discuss the results that day at 8:30 a.m. EDT (5:30 a.m. PDT). To join the call dial 877-407-8035 (Domestic) or 201-689-8035 (Internat
Jun 15, 2021 09:00 am ET
Champions Oncology and BGI Americas Announce a Strategic Partnership to Provide Mass Spectrometry Proteomics, Metabolomics, and Multi-Omic Data Analysis Solutions
HACKENSACK, NJ / ACCESSWIRE / June 15, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Americas.
Mar 11, 2021 04:00 pm ET
Champions Oncology Reports Record Quarterly Revenue of $10.8 Million
Third Quarter and Recent Highlights:
Mar 05, 2021 08:30 am ET
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 11, 2021
HACKENSACK, NJ / ACCESSWIRE / March 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced it will report its financial and operational results for the third quarter ended January 31, 2021, on Thursday, March 11, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). To join the call dial 877-407-8035 (Domestic) or 201-689-8035 (Intern
Feb 22, 2021 09:00 am ET
Champions Oncology Announces Addition to Board of Directors
HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also annou
Jan 19, 2021 09:00 am ET
Champions Oncology Announces Partnership with Code Ocean to Expand the Functionality of Lumin Bioinformatics
HACKENSACK, NJ / ACCESSWIRE / January 19, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today a partnership with Code Ocean to expand the functionality of its SaaS program, Lumin Bioinformatics. The partnership between Champions and Code Ocean will focus on enhancements involved in data integration and sharing workflows within the Lumin platform. Users will now be equipped with a robust methodology f
Jan 05, 2021 08:30 am ET
Champions Oncology Announces the Expansion of Lumin Bioinformatics: Now Featuring a Highly Valuable Set of Proteomic Data and Analytics
HACKENSACK, NJ / ACCESSWIRE / January 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today the expansion of its SaaS program, Lumin Bioinformatics. Since its launch, Champions has been adding to the data and functionality housed within Lumin, which now features 20,000+ datasets including rare and valuable quantitative phospho-proteomics. To aid in the analysis of this proteomic data, engineers at C
Dec 14, 2020 04:00 pm ET
Champions Oncology Reports Record Quarterly Revenue of $10.1 Million
Launches Lumin Bioinformatics SaaS platform
Dec 07, 2020 04:00 pm ET
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 14, 2020
HACKENSACK, NJ / ACCESSWIRE / December 7, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced it will report its financial and operational results for the second quarter ended October 31, 2020, on Monday, December 14, 2020, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). To join the call dial 877-407-8035 (Domestic) or 201-689-8035 (I
Nov 16, 2020 04:40 pm ET
Champions Oncology Announces the Launch of Lumin Bioinformatics, Its New Oncology Data-Driven SaaS Program
HACKENSACK, NJ / ACCESSWIRE / November 16, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of its new proprietary SaaS program known as Lumin Bioinformatics. By leveraging Champions' large cancer dataset, which is unique for its substantial depth of characterization, combined with many other published cancer datasets, Lumin provides users with a vast data
Nov 11, 2020 09:00 am ET
Champions Oncology Expands Its Immuno-Oncology Research Offering by Launching a Unique Autologous Tumor Infiltrating Lymphocyte Ex Vivo Platform
HACKENSACK, NJ / ACCESSWIRE / November 11, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of a novel autologous immuno-oncology (IO) research platform. This autologous tumor infiltrating lymphocyte (TIL) ex vivo platform centers on the use of a tumor and an immune system derived from the same patient for investigations in the immuno-oncology space.
Sep 14, 2020 04:00 pm ET
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million
HACKENSACK, NJ / ACCESSWIRE / September 14, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2020.
Sep 08, 2020 04:30 pm ET
Champions Oncology to Announce First Quarter Financial Results on Monday, September 14, 2020
HACKENSACK, NJ / ACCESSWIRE / September 8, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2020, on Monday, September 14, 2020, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). To join the call dial 877-407-8035 (Domestic) or 201-689-8035 (International)
Jul 27, 2020 04:01 pm ET
Champions Oncology Reports Quarterly Revenue of $8.8 Million
Record Annual Revenue of $32.1 Million
Jul 22, 2020 08:00 am ET
Champions Oncology to Announce Fourth Quarter Financial Results on Monday, July 27, 2020
HACKENSACK, NJ / ACCESSWIRE / July 22, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the quarter and year ended April 30, 2020, on Monday, July 27, 2020, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). To join the call dial 877-407-8035 (Domestic) or 201-689-8035 (International). A r
Mar 12, 2020 04:17 pm ET
Champions Oncology Reports Record Quarterly Revenue of $9.0 Million
HACKENSACK, NJ / ACCESSWIRE / March 12, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the third fiscal quarter ended January 31, 2020.
Mar 10, 2020 08:30 am ET
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2020
HACKENSACK, NJ / ACCESSWIRE / March 10, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2020, on Thursday, March 12, 2019, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). To join the call dial 877-407-8035 (Domestic) or 201-689-8035 (International).
Jan 29, 2020 09:00 am ET
The Children's Cancer Therapy Development Institute is collaborating with Champions Oncology and The Jackson Laboratory to provide RACE Act/PREA pediatric cancer study plan services
The Children's Cancer Therapy Development Institute (cc-TDI), Champions Oncology, and The Jackson Laboratory offer rapid, cost-effective services to the pharma, biopharma and biotech industry- speeding the right drug to the right pediatric cancer whenever possible.
Dec 16, 2019 04:00 pm ET
Champions Oncology Reports Quarterly Revenue of $7.6 Million
Records Second Quarter Income of $291,000
Dec 09, 2019 08:30 am ET
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 16, 2019
HACKENSACK, NJ / ACCESSWIRE / December 9, 2019 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2019, on Monday, December 16, 2019, after market close.
Nov 13, 2019 05:00 pm ET
Champions Oncology and PhenoVista Biosciences Announce a Strategic Partnership to provide Oncology Imaging-based Phenotypic Assays for Preclinical Drug Development
HACKENSACK, NJ / ACCESSWIRE / November 13, 2019 / Champions Oncology (NASDAQ:CSBR), an end-to-end R&D Oncology solutions company announced today that they have entered into a strategic partnership with PhenoVista Biosciences.
Sep 16, 2019 04:00 pm ET
Champions Oncology Reports Quarterly Revenue of $6.7 Million
HACKENSACK, NJ / ACCESSWIRE / September 16, 2019 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2019.
Sep 09, 2019 08:30 am ET
Champions Oncology to Announce First Quarter Financial Results on Monday, September 16, 2019
HACKENSACK, NJ / ACCESSWIRE / September 9, 2019 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2019, on Monday, September 16, 2019, after market close.
Jul 15, 2019 04:35 pm ET
Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019
Record Annual Revenue of $27 Million
May 30, 2019 08:30 am ET
Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations
HACKENSACK, NJ / ACCESSWIRE / May 30, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions' translational oncology tools throughout Europe.
Mar 18, 2019 04:00 pm ET
Champions Oncology Reports Quarterly Revenue of $6.4 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019
Mar 06, 2019 08:30 am ET
Champions Oncology to Announce Third Quarter Financial Results on Monday, March 18, 2019
HACKENSACK, NJ / ACCESSWIRE / March 6, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2019, on Monday, March 18, 2019, after market close.
Dec 17, 2018 04:30 pm ET
Champions Oncology Participates in Pre-Clinical Studies to Identify Novel Therapy for Childhood Cancer
HACKENSACK, NJ / ACCESSWIRE / December 17, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced, in partnership with Drs. Narendra Bharathy and Charles Keller at the Children's Cancer Therapy Development Institute (cc-TDI), the publication of in-vivo oncology pharmacology data presenting the effectiveness of the investigational drug entinostat in Patient Derived Xenograft (PDX) mode
Dec 17, 2018 04:00 pm ET
Champions Oncology Reports Quarterly Revenue of $6.7 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019
Dec 10, 2018 03:30 pm ET
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018
HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018.
Nov 15, 2018 07:20 am ET
Analysis: Positioning to Benefit within Red Lion Hotels, P.A.M. Transportation Services, Champions Oncology, Kingstone Companies, Applied DNA Sciences, and Innodata — Research Highlights Growth, Reven
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Red Lion Hotels Corporation (NYSE:RLH), P.A.M. Transportation Services,...
Nov 07, 2018 07:30 am ET
Champions Oncology to Participate in the 9th Annual Craig-Hallum Alpha Select Conference
HACKENSACK, N.J., Nov. 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management, will participate in the 9th annual Craig-Hallum Alpha Select conference on Thursday, November 15, 2018, in New York.
Sep 13, 2018 04:05 pm ET
Champions Oncology Reports Record Quarterly Revenue of $6.2 Million
HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2018.
Sep 13, 2018 08:30 am ET
Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York
HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at the Janney Montgomery Scott Healthcare Conference 2018 on Monday, September 17th in New York.
Aug 28, 2018 08:30 am ET
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 13, 2018
HACKENSACK, N.J., Aug. 28, 2018 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2018, on Thursday, September 13, 2018, after market close.
Aug 08, 2018 08:30 am ET
Champions Oncology Granted Full Accreditation by the AAALAC
HACKENSACK, N.J., Aug. 8, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that its new facility in Rockville, MD has been granted Full Accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. AAALAC commended Champions for the quality and dedication of the staff, the superior quality of the animal facilities, the excellent program of veterinary medical care, and the highly kn
Jul 26, 2018 04:02 pm ET
Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018
HACKENSACK, N.J., July 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter and 12 months ended April 30, 2018.
Jul 12, 2018 08:30 am ET
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 26, 2018
HACKENSACK, N.J., July 12, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2018, on Thursday, July 26, 2018, after market close.
Jun 18, 2018 08:30 am ET
Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies
HACKENSACK, N.J., June 18, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (Nasdaq: PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials.
May 03, 2018 08:30 am ET
Champions Oncology to Present at the 3rd annual Disruptive Growth & Healthcare Conference on May 9th
HACKENSACK, N.J., May 3, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith's offices located at 599 Lexington Avenue.
May 01, 2018 08:30 am ET
Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research
HACKENSACK, N.J., May 1, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research.
Apr 04, 2018 08:30 am ET
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House
HACKENSACK, N.J., April 4, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year's MicroCap Conference on Tuesday, April 10, 2018 at 9:30am.
Mar 15, 2018 04:01 pm ET
Champions Oncology Reports Quarterly Revenue of $5.1 Million
HACKENSACK, N.J., March 15, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal quarter and nine months ended January 31, 2018.
Mar 07, 2018 07:30 am ET
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018
HACKENSACK, N.J., March 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2018, on Thursday, March 15, 2018, after market close.
Feb 26, 2018 07:30 am ET
Champions Oncology to Participate at the 30th Annual ROTH Conference
HACKENSACK, N.J., Feb. 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th Annual Roth Conference and will conduct one-on-one meetings.
Feb 21, 2018 07:30 am ET
Motivated Patients with ROS1 Cancer Initiate Global Research Study
SAN CARLOS, Calif. and HACKENSACK, N.J., Feb. 21, 2018 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for ROS1-fusion driven cancers to understand what drives tumor development, therapeutic response and acquired resistance to enable the development of new and more effective therapies against this under-studied molecular subset of cancer.
Dec 07, 2017 03:15 pm ET
Champions Oncology Reports Record Quarterly Revenue of $5.2 Million
HACKENSACK, N.J., Dec. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second fiscal quarter and six months ended October 31, 2017.
Nov 28, 2017 07:05 am ET
Champions Oncology to Announce Second Quarter Financial Results on Thursday, December 7, 2017
HACKENSACK, N.J., Nov. 28, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2017, on Thursday, December 7, 2017, after market close.
Nov 07, 2017 08:00 am ET
Champions Oncology to Participate in the Craig-Hallum Alpha Select Investor Conference
HACKENSACK, N.J., Nov. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, will be participating in the 8th Annual Craig-Hallum Alpha Select Conference on November 16th. The conference is being held at the Sheraton New York Times Square Hotel in New York City.
Sep 26, 2017 09:30 am ET
Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models
HACKENSACK, N.J., Sept. 26, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the signing of a competitive contract through the government's Small Business Innovation Research (SBIR) program. The contract is in response to Topic 355 – Cell and Animal-Based Models to Advance Cancer Ethnic Health Disparity Research. Champions' direct-to-Phase II proposal, entitled "Metastatic Prostate Cancer Patient Derived Xenograft M
Sep 18, 2017 10:15 am ET
Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies
HACKENSACK, N.J., Sept. 18, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the publication entitled "Patient-derived xenografts (PDX) effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors" in the journal Annals of Oncology. Annals of Oncology is published by the European Society for Medical oncology (ESMO), the leading European professional organization for med
Sep 14, 2017 05:30 pm ET
Champions Oncology Reports Record Quarterly Revenue of $5 Million
HACKENSACK, N.J., Sept. 14, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2017.
Sep 07, 2017 06:00 pm ET
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 14, 2017
HACKENSACK, N.J., Sept. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2017, on Thursday, September 14, 2017, after market close.
Aug 21, 2017 09:30 am ET
Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models
HACKENSACK, N.J., Aug. 21, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca's oncology R&D programs in breast and lung cancer, in addition to being added to Champions' existing TumorGraft bank for translational oncology research for academic and industry customers. Champions' global network
Aug 18, 2017 09:30 am ET
Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort of Patient-Derived Xenograft (PDX) Models
HACKENSACK, N.J., Aug. 18, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a collaboration with The Addario Lung Cancer Medical Institute "ALCMI" to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement. These models will further expand Champions' TumorGraft bank offerings in non-small cell lung cancer for translational oncology research for academic and industry customers. Champions' glob
Aug 15, 2017 05:57 am ET
The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer
SAN CARLOS, Calif. and HACKENSACK, N.J., Aug. 15, 2017 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR), and the ROS1ders (voiced as "ross wonders") announce a preclinical study that will develop new models of cancers expressing a ROS1 gene rearrangement. This study is part of The Global ROS1 Research Initiative, which focuses on improving outcomes for this uncommon yet clinically important oncogene-driven cancer. The strength and novelty of the initiative stems from the ROS1ders driving the collaboration among cancer advocacy organizations
Jul 27, 2017 05:01 pm ET
Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017
HACKENSACK, N.J., July 27, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth quarter and year ended April 30, 2017.
Jul 17, 2017 09:30 am ET
Champions Oncology Schedules Fourth Quarter and Fiscal Year 2017 Earnings Call
HACKENSACK, N.J., July 17, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2017, on Thursday, July 27, 2017, after market close.
Mar 16, 2017 05:01 pm ET
Champions Oncology Reports 40% Revenue Growth
HACKENSACK, N.J., March 16, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2017.
Mar 16, 2017 10:00 am ET
Champions Oncology Announces Plan to Open New Lab Facility in Rockville, Maryland
HACKENSACK, N.J., March 16, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced plans for opening a new lab facility in Rockville, Maryland during the second quarter of its 2018 fiscal year. At current levels of business, the Company expects to realize a 10% reduction in lab costs.
Mar 07, 2017 08:00 am ET
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 16, 2017
HACKENSACK, N.J., March 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2017, on Thursday, March 16, 2017, after market close.
Feb 16, 2017 09:36 am ET
Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research
HACKENSACK, N.J., Feb. 16, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the addition of new cohorts of PDX models to their existing TumorBank.
Jan 19, 2017 10:38 am ET
Champions Oncology Retains Hayden IR to Execute Comprehensive Investor Relations Program
HACKENSACK, N.J., Jan. 19, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it has retained Hayden IR, a premier national investor relations consulting firm, to develop and execute strategic investor relations campaigns designed to increase awareness and enhance shareholder value.
Nov 29, 2016 04:15 pm ET
Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior Leadership
HACKENSACK, N.J., Nov. 29, 2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2016.
Nov 23, 2016 10:20 am ET
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, November 29, 2016
HACKENSACK, N.J., Nov. 23, 2016 /PRNewswire/ -- Champions Oncology (NASDAQ: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2016, on Tuesday, November 29, 2016, after market close.
Nov 17, 2016 04:05 pm ET
Champions Oncology Signs $2 million Contract
HACKENSACK, N.J., Nov. 17, 2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today the signing of a $2 million contract with a large pharmaceutical customer. This is the largest pre-clinical pharmacology contract in the company's history and is almost double the size of the largest previous contract. The contract includes studies utilizing Champions patient derived xenograft (PDX) models and a significant component of work on immune oncolo
Sep 09, 2016 09:15 am ET
Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year Guidance of 43 - 60% Revenue Growth
HACKENSACK, N.J., Sept. 9, 2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2016.
Sep 06, 2016 09:30 am ET
Champions Oncology to Announce First Quarter Financial Results on Friday, September 9, 2016
HACKENSACK, N.J., Sept. 6, 2016 /PRNewswire/ -- Champions Oncology (NASDAQ: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2016, on Friday, September 9, 2016, before market open.
Jul 28, 2016 09:00 am ET
Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year
HACKENSACK, N.J., July 28, 2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2016.
Jul 25, 2016 07:18 pm ET
Champions Oncology to Announce Year-End 2016 Financial Results on Thursday, July 28, 2016
HACKENSACK, N.J., July 25, 2016 /PRNewswire/ -- Champions Oncology (NASDAQ: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year quarter ended April 30, 2016, on Thursday, July 28, 2016, before market open.
Jul 18, 2016 09:30 am ET
Champions Oncology Successfully Delivers First AML Study
HACKENSACK, N.J., July 18, 2016 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the successful completion of its first study in acute myeloid leukemia (AML). Champions Oncology identified AML as an area of significant unmet customer need and has been pursuing two technological approaches for developing AML models in conjunction with external collaborators. The first approach involves AML modeling from banked patient s
Jun 15, 2016 01:00 pm ET
Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock
HACKENSACK, N.J., June 15, 2016 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), or the "Company", a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the closing of its previously announced underwritten public offering of 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, the Company announced today the partial exercise of the over-allotment option granted to the underwriter to purchase
Jun 09, 2016 08:30 pm ET
Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock
HACKENSACK, N.J., June 9, 2016 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), or the "Company", a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the pricing of its previously announced underwritten public offering. The Company is offering 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, Champions Oncology, Inc. has granted the underwriter a 45-day over-allotment option to purchase up to
Apr 12, 2016 01:30 pm ET
Champions Oncology Announces Addition to Board of Directors
HACKENSACK, N.J., April 12, 2016 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ:CSBR) is pleased to announce the appointment of Dr. Philip Breitfeld to its Board of Directors. Dr. Breitfeld has more than 30 years of experience in oncology. His appointment will further the company's efforts to accelerate growth and increase the adoption of its technology platform.
Mar 15, 2016 09:30 am ET
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016
HACKENSACK, N.J., March 15, 2016 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2016.
Mar 11, 2016 09:00 am ET
Champions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016
HACKENSACK, N.J., March 11, 2016 /PRNewswire/ -- Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will be presenting at the 28th Annual ROTH Capital Conference on Wednesday, March 16, 2016. The Conference will be held at the Ritz Carlton in Dana Point, California from March 13 – 16, 2016.
Mar 10, 2016 10:00 am ET
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016
HACKENSACK, N.J., March 10, 2016 /PRNewswire/ -- Champions Oncology (NASDAQ: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2016, on Tuesday, March 15, 2016, before the market open.
Jan 21, 2016 11:00 am ET
Champions Oncology Announces Initiation of Prospective Correlative Trial in Sarcoma
HACKENSACK, N.J., Jan. 21, 2016 /PRNewswire/ -- Champions Oncology (NASDAQ:CSBR) today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft® PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.